Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesEmyria Ltd

Emyria Ltd

Healthcare Health Information Services
PortfolioPortfolio WatchlistWatchlist
Company price
0.036 AUD -0.00 ( 5.26%)
Last update at 2026-11-09T05:10:00Z
VOLUME
979814
Market Cap
30.65M

Momentum Score

…

Emyria Limited engages in delivering and developing of treatments for mental health and select neurological conditions in Australia. The company operates through Clinical Services and corporate segments. It provides therapy programs for post-traumatic stress disorder (PTSD) and treatment-resistant depression. The company also develops ultra-pure CBD capsules (EMD-RX7, and EMD-RX9) and proprietary MDMA analogues, as well as provides psychological trauma care facility under the Pax Centre name. It has a collaboration partnership with the University of Western Australia to support the expand Emyria's MDMA analogue drug development program. The company was formerly known as Emerald Clinics Limited and changed its name to Emyria Limited in September 2020. Emyria Limited was incorporated in 2018 and is headquartered in Subiaco, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.04
Low
0.04
High
52 Week Price Range
0.04
Low
0.08
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Emyria Limited is an Australian clinical-stage healthcare company that provides clinical research, patient registry and support services while developing therapeutics for neurological and psychiatric disorders, leveraging real-world data and trial capabilities to advance programs. Major long-term growth drivers include rising demand for new mental-health treatments, wider acceptance of data-driven evidence in care and potential revenue from service operations and partnered development, which may benefit investors seeking exposure to therapeutic development with an operational services base.

Key investment risks include clinical and regulatory setbacks for its development programs, funding and commercialization execution risk, and competition from larger pharmaceutical and specialist clinical-service providers.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.04
Dividend Yield
-
Revenue TTM
4.05M
Revenue Per Share
0.01
Gross Profit TTM
0.92M
Debt / Equity
0.09
ROE
-86.42%
Net Debt
-6.50M
ROCE
-65.74%
Diluted EPS TTM
-0.01

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -6.31M -3.14M -13.98M -5.13M -7.33M
Net income -6.11M -3.14M -11.46M -5.13M -7.33M
Selling general administrative - 3.52M 3.43M 3.43M 4.61M
Selling and marketing expenses - - 1.62M - -
Gross profit -3.66M 0.02M -0.17M -0.65M -1.00M
Reconciled depreciation - - 0.69M 0.40M 0.39M
Ebit -6.27M -2.49M -13.73M -4.88M -7.26M
Ebitda -5.81M -2.39M -13.03M -4.48M -6.87M
Depreciation and amortization 0.46M 0.10M 0.69M 0.40M 0.39M
Operating income -6.27M -2.65M -6.90M -4.24M -6.85M
Other operating expenses 10.15M 4.04M 9.11M 2.15M 4.40M
Interest expense 0.06M 0.13M 0.25M 0.13M 0.07M
Tax provision - 0.00M 0.00M 0.00M 0.00M
Interest income - - 0.02M 0.03M 0.01M
Net interest income - - -0.23M -0.10M -0.06M
Income tax expense -0.19M - -2.53M 2.34M 1.81M
Total revenue 3.88M 1.39M 2.20M 1.59M 1.35M
Total operating expenses 2.61M 2.67M 6.74M 6.48M 8.01M
Cost of revenue 7.54M 1.37M 2.37M 2.24M 2.35M
Total other income expense net -0.04M -0.50M -7.08M 2.09M 1.74M
Net income from continuing ops - - -11.46M -5.13M -7.33M
Net income applicable to common shares - -3.14M -11.46M -5.13M -7.33M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 11.49M 6.62M 5.43M 10.16M 8.25M
Intangible assets 0.18M 0.00M - 6.67M 2.89M
Other current assets 0.12M 0.22M 0.33M 0.05M 0.15M
Total liab 2.65M 1.31M 3.00M 3.37M 1.93M
Total stockholder equity 8.85M 5.31M 2.43M 6.79M 6.32M
Other current liab 0.88M 0.30M 0.71M 2.03M 0.84M
Common stock 50.97M 41.89M 36.26M 29.80M 24.64M
Capital stock - - - 29.80M 24.64M
Retained earnings -44.06M -38.04M -35.35M -25.42M -20.29M
Other liab - - - 0.08M 0.11M
Good will 1.32M 1.56M 1.56M - -
Other assets - - - 0.14M 0.16M
Cash 7.29M 3.57M 1.57M 2.73M 3.88M
Total current liabilities 1.96M 0.80M 2.24M 3.15M 1.46M
Current deferred revenue 0.00M - 0.00M -1.84M -0.27M
Net debt -6.50M -2.96M 0.15M -1.46M -3.25M
Short term debt 0.13M 0.13M 1.03M 1.13M 0.27M
Short long term debt - - - 0.91M -
Short long term debt total 0.79M 0.61M 1.72M 1.27M 0.63M
Other stockholder equity - - - -4.39M -4.35M
Property plant equipment - - - 0.50M 1.08M
Total current assets 8.53M 3.81M 1.93M 2.85M 4.12M
Net tangible assets - - - 0.12M 3.43M
Net receivables 0.79M 0.02M 0.03M 0.09M 0.09M
Inventory 0.33M - - - -
Accounts payable 0.95M 0.37M 0.50M 1.83M 0.62M
Accumulated other comprehensive income 1.93M 1.45M 1.51M 2.41M 1.97M
Non currrent assets other - 0.38M 0.52M 0.14M 0.16M
Non current assets total 2.96M 2.81M 3.50M 7.31M 4.13M
Capital lease obligations - - - 0.36M 0.63M
Long term debt total - - - 0.14M 0.36M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - - -1.38M -3.23M -2.03M
Change to liabilities - - - 0.42M 0.06M
Total cashflows from investing activities -0.55M 0.08M -1.38M -3.23M -2.03M
Net borrowings - - -0.28M 0.66M -0.23M
Total cash from financing activities 8.82M 4.63M 4.50M 5.84M 4.81M
Change to operating activities - - - 0.11M 0.05M
Net income -6.11M -3.14M -11.46M -5.13M -7.33M
Change in cash 3.72M 2.00M -1.17M -1.15M -2.65M
Begin period cash flow 3.57M 1.57M 2.73M 3.88M 6.53M
End period cash flow 7.29M 3.57M 1.57M 2.73M 3.88M
Total cash from operating activities -4.56M -2.70M -4.28M -3.77M -5.43M
Issuance of capital stock - - 5.16M 5.50M 5.04M
Depreciation 0.46M 0.47M 0.69M 0.32M 0.31M
Other cashflows from investing activities -0.18M 0.09M -1.08M -3.22M 0.00M
Dividends paid - - - - 0.77M
Change to inventory -0.33M - - - -
Change to account receivables -0.76M -0.01M 0.05M 0.00M 0.08M
Sale purchase of stock - 5.73M -0.14M 5.50M -0.53M
Other cashflows from financing activities -0.12M -0.81M -0.28M 1.14M 1.30M
Change to netincome - - - 0.43M 1.32M
Capital expenditures 0.37M 0.01M 0.16M 3.23M 2.03M
Change in working capital 0.17M -0.00M -0.28M 0.00M 0.08M
Stock based compensation - 0.41M 0.36M 0.42M 1.43M
Other non cash items 0.93M -0.43M 6.40M 1.04M 1.59M
Free cash flow -4.92M -2.72M -4.44M -7.01M -7.46M

Peer Comparison*

Sector: Healthcare Industry: Health Information Services

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
EMD
Emyria Ltd		 -0.00
5.26%		 0.04 - - 7.56 3.65 6.64 -7.15
PME
Pro Medicus Ltd		 0.36
0.18%		 205.49 81.98 106.38 83.13 43.70 74.38 95.34
4DX
4DMEDICAL Ltd		 0.06
2.63%		 2.34 - - 205.57 8.53 170.03 -7.29
CGS
Cogstate Ltd		 0.07
2.13%		 3.36 33.80 27.86 9.59 6.95 6.35 19.27
AYA
ARTRYA Ltd		 -0.02
0.57%		 3.48 - - 20505.14 7.00 16927.51 0.33

Profile*

Emyria Ltd

Emyria Limited engages in delivering and developing of treatments for mental health and select neurological conditions in Australia. The company operates through Clinical Services and corporate segments. It provides therapy programs for post-traumatic stress disorder (PTSD) and treatment-resistant depression. The company also develops ultra-pure CBD capsules (EMD-RX7, and EMD-RX9) and proprietary MDMA analogues, as well as provides psychological trauma care facility under the Pax Centre name. It has a collaboration partnership with the University of Western Australia to support the expand Emyria's MDMA analogue drug development program. The company was formerly known as Emerald Clinics Limited and changed its name to Emyria Limited in September 2020. Emyria Limited was incorporated in 2018 and is headquartered in Subiaco, Australia.

Level 1, 516 Hay Street, Subiaco, WA, Australia, 6008

61 8 6559 2800

https://emyria.com

Name Title Year Born
Dr. Stewart James Washer B.Sc., BSc (Hons), Ph.D. Exec. Chairman 1970
Dr. Michael Winlo MD & Director NA
Dr. Alistair Vickery Exec. Medical Director & Director NA
Dr. Karen L. Smith L.L.M, L.L.M., M.B.A., M.D., PH.D. Exec. Director & Chairman of Strategic Advisory Board 1968
Mr. Joseph Daniel Ohayon ACA, MBA Intl Bus. Chief Financial Officer NA
Ms. Tracie Ernenwein Head of Research & Drug Devel. NA
Mary-Ann Rennie Head of Corp. Operations NA
Mr. Simon Robertson C.A., B.Bus, M Appl. Fin, CA Company Sec. NA
Mary-Ann Rennie Head of Corporate Operations NA
Dr. Alistair Vickery Executive Medical Director & Director NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…